Limits...
Effect of Luteolin on 11Beta-Hydroxysteroid Dehydrogenase in Rat Liver and Kidney.

Tang L, Deng B, Shi L, Wei B, Ren B, Fu X - Evid Based Complement Alternat Med (2015)

Bottom Line: In this paper, we chose Luteolin which is one of the main ingredients of EP and evaluated its effect and metabolism in combination with prednisone.Our results showed that oral administration of Luteolin significantly increased the gene and protein expressions of hepatic 11β-HSD I and renal 11β-HSD II, which may improve the efficacy and reduce the adverse drug effect of glucocorticoid in clinical application.A potential clinical value of Luteolin would also be indicated in combination therapy with prednisone for the treatment of nephrotic syndrome.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacy, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan No. 2 Road, Guangzhou, Guangdong 510080, China.

ABSTRACT
11Beta-hydroxysteroid dehydrogenase (11β-HSD) enzymes control the glucocorticoid (GC) signaling, which is essential in regulating homeostasis. Our previous study revealed that Eclipta prostrata (EP) affected the activity and expression of 11β-HSD enzymes which might improve the efficacy and reduce the adverse drug effects of glucocorticoid in patients undergoing combinational therapy. However, it is still unclear which composition of EP plays a major role and how it works. In this paper, we chose Luteolin which is one of the main ingredients of EP and evaluated its effect and metabolism in combination with prednisone. The effects of different concentrations of Luteolin extract on prednisone/prednisolone metabolism indicated the enzyme activity of 11β-HSD, so the production rate (pmol/min per mg protein) of metabolites was used to indicate enzyme activity. Furthermore, we explored the influence of Luteolin on gene and protein expressions of 11β-HSD I/II in rat liver and kidney tissue. Our results showed that oral administration of Luteolin significantly increased the gene and protein expressions of hepatic 11β-HSD I and renal 11β-HSD II, which may improve the efficacy and reduce the adverse drug effect of glucocorticoid in clinical application. A potential clinical value of Luteolin would also be indicated in combination therapy with prednisone for the treatment of nephrotic syndrome.

No MeSH data available.


Related in: MedlinePlus

Effects of Luteolin on the protein expression of 11β-HSD I and 11β-HSD II in rat liver (a and b) and kidney (c and d). Rats were orally administrated with vehicle (CMC-Na) or Luteolin (5 mg/kg, 10 mg/kg, or 20 mg/kg) for 14 days. Liver and kidney were harvested and then 11β-HSD I and 11β-HSD II protein levels were analyzed. Data are expressed as fold change over the control group (mean ± SD, n = 6) ∗P < 0.05, ∗∗P < 0.01. 1, 2: control group; 3, 4: Luteolin 5 mg/kg; 5, 6: Luteolin 10 mg/kg; 7, 8: Luteolin 20 mg/kg.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4496493&req=5

fig3: Effects of Luteolin on the protein expression of 11β-HSD I and 11β-HSD II in rat liver (a and b) and kidney (c and d). Rats were orally administrated with vehicle (CMC-Na) or Luteolin (5 mg/kg, 10 mg/kg, or 20 mg/kg) for 14 days. Liver and kidney were harvested and then 11β-HSD I and 11β-HSD II protein levels were analyzed. Data are expressed as fold change over the control group (mean ± SD, n = 6) ∗P < 0.05, ∗∗P < 0.01. 1, 2: control group; 3, 4: Luteolin 5 mg/kg; 5, 6: Luteolin 10 mg/kg; 7, 8: Luteolin 20 mg/kg.

Mentions: As shown in Figure 3, the relative protein expression levels of 11β-HSD I/II in rat liver and kidney were investigated by western blot analysis. Compared with control group, the protein expressions of 11β-HSD I in rat liver treated with Luteolin (5, 10, and 20 mg/kg) were increased by 26%, 49%, and 66%, respectively (Figure 3(a)), whereas the protein expressions of 11β-HSD II were reduced by 24%, 34%, and 56%, respectively (Figure 3(b)). In contrast, the protein expressions of 11β-HSD II in rat kidney treated with Luteolin (5, 10, and 20 mg/kg) were increased by 47%, 55%, and 84%, respectively, while those of 11β-HSD I were decreased by 32%, 37%, and 47%, respectively (Figures 3(c) and 3(d)). The influence of Luteolin on protein expression of 11β-HSD showed dose-dependent relationship, and high-dose group had the most significant effect. Therefore, Luteolin upregulated the protein expression of 11β-HSD I and downregulated the protein expression of 11β-HSD II in liver. The effects of Luteolin on the protein expression of 11β-HSD II and 11β-HSD I in kidney were opposite compared with those in liver.


Effect of Luteolin on 11Beta-Hydroxysteroid Dehydrogenase in Rat Liver and Kidney.

Tang L, Deng B, Shi L, Wei B, Ren B, Fu X - Evid Based Complement Alternat Med (2015)

Effects of Luteolin on the protein expression of 11β-HSD I and 11β-HSD II in rat liver (a and b) and kidney (c and d). Rats were orally administrated with vehicle (CMC-Na) or Luteolin (5 mg/kg, 10 mg/kg, or 20 mg/kg) for 14 days. Liver and kidney were harvested and then 11β-HSD I and 11β-HSD II protein levels were analyzed. Data are expressed as fold change over the control group (mean ± SD, n = 6) ∗P < 0.05, ∗∗P < 0.01. 1, 2: control group; 3, 4: Luteolin 5 mg/kg; 5, 6: Luteolin 10 mg/kg; 7, 8: Luteolin 20 mg/kg.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4496493&req=5

fig3: Effects of Luteolin on the protein expression of 11β-HSD I and 11β-HSD II in rat liver (a and b) and kidney (c and d). Rats were orally administrated with vehicle (CMC-Na) or Luteolin (5 mg/kg, 10 mg/kg, or 20 mg/kg) for 14 days. Liver and kidney were harvested and then 11β-HSD I and 11β-HSD II protein levels were analyzed. Data are expressed as fold change over the control group (mean ± SD, n = 6) ∗P < 0.05, ∗∗P < 0.01. 1, 2: control group; 3, 4: Luteolin 5 mg/kg; 5, 6: Luteolin 10 mg/kg; 7, 8: Luteolin 20 mg/kg.
Mentions: As shown in Figure 3, the relative protein expression levels of 11β-HSD I/II in rat liver and kidney were investigated by western blot analysis. Compared with control group, the protein expressions of 11β-HSD I in rat liver treated with Luteolin (5, 10, and 20 mg/kg) were increased by 26%, 49%, and 66%, respectively (Figure 3(a)), whereas the protein expressions of 11β-HSD II were reduced by 24%, 34%, and 56%, respectively (Figure 3(b)). In contrast, the protein expressions of 11β-HSD II in rat kidney treated with Luteolin (5, 10, and 20 mg/kg) were increased by 47%, 55%, and 84%, respectively, while those of 11β-HSD I were decreased by 32%, 37%, and 47%, respectively (Figures 3(c) and 3(d)). The influence of Luteolin on protein expression of 11β-HSD showed dose-dependent relationship, and high-dose group had the most significant effect. Therefore, Luteolin upregulated the protein expression of 11β-HSD I and downregulated the protein expression of 11β-HSD II in liver. The effects of Luteolin on the protein expression of 11β-HSD II and 11β-HSD I in kidney were opposite compared with those in liver.

Bottom Line: In this paper, we chose Luteolin which is one of the main ingredients of EP and evaluated its effect and metabolism in combination with prednisone.Our results showed that oral administration of Luteolin significantly increased the gene and protein expressions of hepatic 11β-HSD I and renal 11β-HSD II, which may improve the efficacy and reduce the adverse drug effect of glucocorticoid in clinical application.A potential clinical value of Luteolin would also be indicated in combination therapy with prednisone for the treatment of nephrotic syndrome.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacy, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan No. 2 Road, Guangzhou, Guangdong 510080, China.

ABSTRACT
11Beta-hydroxysteroid dehydrogenase (11β-HSD) enzymes control the glucocorticoid (GC) signaling, which is essential in regulating homeostasis. Our previous study revealed that Eclipta prostrata (EP) affected the activity and expression of 11β-HSD enzymes which might improve the efficacy and reduce the adverse drug effects of glucocorticoid in patients undergoing combinational therapy. However, it is still unclear which composition of EP plays a major role and how it works. In this paper, we chose Luteolin which is one of the main ingredients of EP and evaluated its effect and metabolism in combination with prednisone. The effects of different concentrations of Luteolin extract on prednisone/prednisolone metabolism indicated the enzyme activity of 11β-HSD, so the production rate (pmol/min per mg protein) of metabolites was used to indicate enzyme activity. Furthermore, we explored the influence of Luteolin on gene and protein expressions of 11β-HSD I/II in rat liver and kidney tissue. Our results showed that oral administration of Luteolin significantly increased the gene and protein expressions of hepatic 11β-HSD I and renal 11β-HSD II, which may improve the efficacy and reduce the adverse drug effect of glucocorticoid in clinical application. A potential clinical value of Luteolin would also be indicated in combination therapy with prednisone for the treatment of nephrotic syndrome.

No MeSH data available.


Related in: MedlinePlus